open access

Vol 85, No 4 (2014)
ARTICLES
Get Citation

Non-invasive Fetal Trisomy (NIFTY) test in prenatal diagnosis

Izabela Łaczmańska, Agnieszka Stembalska
DOI: 10.17772/gp/1727
·
Ginekol Pol 2014;85(4).

open access

Vol 85, No 4 (2014)
ARTICLES

Abstract

NIFTY (Non-invasive Fetal Trisomy Test) is a non-invasive prenatal test which is used for diagnosing fetal trisomy. The test is based on the analysis of cell free fetal DNA (cffDNA) present in the plasma and serum of a pregnant woman. NIFTY allows to detect fetal trisomy of chromosomes 13, 18, 21, X and Y and also X monosomy. Abnormal NIFTY results still need to be verified using other diagnostic techniques. However, the sensitivity of NIFTY for trisomy 21, 18 and 13 is estimated at 99%, 97% and 79% respectively, with false positive rate for all examined trisomies and X monosomy of <1%. NIFTY is currently available in Poland as a commercial service, used as a good screening test for common trisomies (apart from ultrasound and biochemical tests) in the case of patient anxiety, and in situation when the patient does not consent to invasive prenatal diagnostic tests. The sensitivity and specificity of NIFTY will most likely be improved as laboratory methods develop, and after a sufficiently large group of pregnant patients has been tested. Therefore, this test may soon become the primary diagnostic tool for common trisomies, allowing to avoid invasive prenatal testing in this indication. With high probability, cffDNA obtained from the serum of pregnant women will also be used with time in the diagnosis of fetal structural chromosomal aberrations and other genetic changes. The aim of our study is to present a new diagnostic method.

Abstract

NIFTY (Non-invasive Fetal Trisomy Test) is a non-invasive prenatal test which is used for diagnosing fetal trisomy. The test is based on the analysis of cell free fetal DNA (cffDNA) present in the plasma and serum of a pregnant woman. NIFTY allows to detect fetal trisomy of chromosomes 13, 18, 21, X and Y and also X monosomy. Abnormal NIFTY results still need to be verified using other diagnostic techniques. However, the sensitivity of NIFTY for trisomy 21, 18 and 13 is estimated at 99%, 97% and 79% respectively, with false positive rate for all examined trisomies and X monosomy of <1%. NIFTY is currently available in Poland as a commercial service, used as a good screening test for common trisomies (apart from ultrasound and biochemical tests) in the case of patient anxiety, and in situation when the patient does not consent to invasive prenatal diagnostic tests. The sensitivity and specificity of NIFTY will most likely be improved as laboratory methods develop, and after a sufficiently large group of pregnant patients has been tested. Therefore, this test may soon become the primary diagnostic tool for common trisomies, allowing to avoid invasive prenatal testing in this indication. With high probability, cffDNA obtained from the serum of pregnant women will also be used with time in the diagnosis of fetal structural chromosomal aberrations and other genetic changes. The aim of our study is to present a new diagnostic method.
Get Citation

Keywords

non-invasive prenatal diagnostics, Trisomy, NIFTY

About this article
Title

Non-invasive Fetal Trisomy (NIFTY) test in prenatal diagnosis

Journal

Ginekologia Polska

Issue

Vol 85, No 4 (2014)

DOI

10.17772/gp/1727

Bibliographic record

Ginekol Pol 2014;85(4).

Keywords

non-invasive prenatal diagnostics
Trisomy
NIFTY

Authors

Izabela Łaczmańska
Agnieszka Stembalska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl